CDKN1B Loss Fuels ER Therapy Resistance in Breast Cancer
In the evolving landscape of breast cancer treatment, hormone receptor-positive (HR+), HER2-negative breast cancer has long presented both opportunities and challenges. Accounting for approximately 70%...
















